Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, Dunford AJ, Tai YT, Chavda SJ, Boehner C, Neuse CJ, Rahmat M, Dutta A, Casneuf T, Verona R, Kastritis E, Trippa L, Stewart C, Walker BA, Davies FE, Dimopoulos MA, Bergsagel PL, Yong K, Morgan GJ, Aguet F, Getz G, Ghobrial IM. Bustoros M, et al. Among authors: walker ba. Nat Commun. 2022 Jun 15;13(1):3449. doi: 10.1038/s41467-022-30694-w. Nat Commun. 2022. PMID: 35705541 Free PMC article.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. Jenner MW, et al. Among authors: walker ba. Blood. 2007 Nov 1;110(9):3291-300. doi: 10.1182/blood-2007-02-075069. Epub 2007 Jul 3. Blood. 2007. PMID: 17609426 Free article.
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Leone PE, et al. Among authors: walker ba. Clin Cancer Res. 2008 Oct 1;14(19):6033-41. doi: 10.1158/1078-0432.CCR-08-0347. Clin Cancer Res. 2008. PMID: 18829482 Free PMC article.
Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Moore HE, et al. Among authors: walker ba. Mol Cancer Ther. 2009 Apr;8(4):762-70. doi: 10.1158/1535-7163.MCT-08-0735. Mol Cancer Ther. 2009. PMID: 19372548 Free article.
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Dickens NJ, et al. Among authors: walker ba. Clin Cancer Res. 2010 Mar 15;16(6):1856-64. doi: 10.1158/1078-0432.CCR-09-2831. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215539 Free PMC article. Clinical Trial.
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. Bagratuni T, et al. Among authors: walker ba. Blood. 2010 Jul 15;116(2):250-3. doi: 10.1182/blood-2010-01-263236. Epub 2010 Apr 26. Blood. 2010. PMID: 20421453 Free article. Clinical Trial.
232 results